<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03394612</url>
  </required_header>
  <id_info>
    <org_study_id>TBRU-dS-RAC-PII</org_study_id>
    <nct_id>NCT03394612</nct_id>
  </id_info>
  <brief_title>Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children</brief_title>
  <official_title>A Phase II, Prospective, Intra-patient Randomised Controlled, Multicentre Study to Evaluate the Safety and Efficacy of an Autologous Bio-engineered Dermo-epidermal Skin Substitute (EHSG-KF) for the Treatment of Full-Thickness Defects in Adults and Children in Comparison to Autologous Split-thickness Skin Grafts (STSG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyss Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Julius Clinical, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sintesi Research Srl</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CUTISS AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial aims to evaluate the efficacy and safety of EHSG-KF (synonym denovoSkin)&#xD;
      in comparison to meshed STSG in adults and children with full-thickness Skin defects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicentre phase II clinical trial will target adults and children with fullt-thickness&#xD;
      skin defects to elucidate the benefit of a tissue-engineered autologous skin substitute.&#xD;
      Particular emphasis, apart from safety, will be placed on efficacy, e.g. scar quality, in&#xD;
      comparison to meshed STSG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2018</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of EHSG-KF in comparison to STSG based on the assessment of scar quality</measure>
    <time_frame>3 months post grafting</time_frame>
    <description>Efficacy of EHSG-KF in comparison to STSG based on the assessment of scar quality, using the POSAS (&quot;Patient and Observer Scar Assessment Scale&quot;). The reported Observer Total Score can range from 1 (best) to 10 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of EHSG-KF in comparison to STSG based on the assessment of scar quality</measure>
    <time_frame>3 months and 1 year +/- 30 days post grafting</time_frame>
    <description>Evaluation of scar quality at experimental area and control area, using Cutometer for elasticity measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of EHSG-KF in comparison to STSG based on the assessment of scar quality</measure>
    <time_frame>3 months and 1 year +/- 30 days post grafting</time_frame>
    <description>Evaluation of scar quality at experimental area and control area, using POSAS (&quot;Patient and Observer Scar Assessment Scale&quot;) Observer Total Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of EHSG-KF in comparison to STSG based on the assessment of scar quality</measure>
    <time_frame>3 months and 1 year +/- 30 days post grafting</time_frame>
    <description>Evaluation of scar quality at experimental area and control area, using POSAS (&quot;Patient and Observer Scar Assessment Scale&quot;) Patient Items and Total Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A Efficacy of EHSG-KF in comparison to STSG based on the assessment of scar quality</measure>
    <time_frame>3 months and 1 year +/- 30 days post grafting</time_frame>
    <description>Evaluation of scar quality at experimental area and control area, using Colormeter for skin colour measurement,.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of EHSG-KF in comparison to STSG based on the assessment of epithelialisation</measure>
    <time_frame>28 +/- 3 days post grafting</time_frame>
    <description>Evaluation of efficacy at experimental area and control area, calculating the epithelialized area as percentage of the total grafted area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of EHSG-KF in comparison to STSG based on the assessment of graft take.</measure>
    <time_frame>4-11 days post grafting</time_frame>
    <description>Evaluation of efficacy at experimental area and control area, assessed by the analysis of the graft take</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of EHSG-KF in comparison to STSG based on the assessment of quality of life.</measure>
    <time_frame>1 +/- 30 days year post grafting</time_frame>
    <description>Evaluation of efficacy of experimental and control treatment, assessed by quality of life questionnaires (&quot;Pediatric quality of life inventory&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of EHSG-KF in comparison to STSG based on the assessment of quality of life.</measure>
    <time_frame>1 +/- 30 days year post grafting</time_frame>
    <description>Evaluation of efficacy of experimental and control treatment, assessed by quality of life questionnaires (&quot;Patient Observer Scar Assessment Scale&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of EHSG-KF in comparison to STSG based on the assessment of quality of life.</measure>
    <time_frame>1 +/- 30 days year post grafting</time_frame>
    <description>Evaluation of efficacy of experimental and control treatment, assessed by quality of life questionnaires (&quot;EuroQuol 5 dimensions questionnaire&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of EHSG-KF in comparison to STSG based on the assessment of quality of life.</measure>
    <time_frame>1 +/- 30 days year post grafting</time_frame>
    <description>Evaluation of efficacy of experimental and control treatment, assessed by quality of life questionnaires (&quot;Burn Specific Health Scale Brief&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of EHSG-KF in comparison to STSG based on the assessment of infection rate.</measure>
    <time_frame>4-11 days and 19-23 days post grafting</time_frame>
    <description>Evaluation of safety at experimental area and control area based on the infection rate, assessed by using wound swabs and clinical evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of EHSG-KF in comparison to STSG based on the assessment of adverse events.</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Evaluation of safety at experimental area and control area, assessed by the type and number of adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Skin Wound</condition>
  <arm_group>
    <arm_group_label>EHSG-KF and STSG Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EHSG-KF</intervention_name>
    <description>Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area</description>
    <arm_group_label>EHSG-KF and STSG Transplantation</arm_group_label>
    <other_name>denovoSkin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>STSG</intervention_name>
    <description>Transplantation of autologous split-thickness skin graft to the control area</description>
    <arm_group_label>EHSG-KF and STSG Transplantation</arm_group_label>
    <other_name>Split-thickness skin graft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: ≥18 years of age&#xD;
&#xD;
          -  Large full-thickness defects that require coverage after excision of: Scars, Benign&#xD;
             skin tumors (e.g. neurofibroma), Melanocytic nevus (e.g. giant nevus), Gender&#xD;
             reassignment surgery, Soft tissue defect after trauma, Soft tissue defect after&#xD;
             infection and debridement (e.g necrotizingn fascitis, hidadentitis suppurativa,&#xD;
             purpura fulminans), Flap donorsite (e.g. radial forearm flap)&#xD;
&#xD;
          -  Minimal areas requiring coverage (not counting the head and neck area for study&#xD;
             patients in The Netherlands): 1-5 years: minimum 9cm2, 6-16 years: minimum 25cm2, &gt;16&#xD;
             years: minimum 45cm2&#xD;
&#xD;
          -  Signed Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients tested positive for HBV, HCV, syphilis or HIV&#xD;
&#xD;
          -  Patients with known underlying or concomitant medical conditions that may interfere&#xD;
             with normal wound healing (e.g. systemic skin and connective tissue diseases, any kind&#xD;
             of congenital defect of metabolism including insulin-dependent diabetes mellitus,&#xD;
             Cushing syndrome or disease, scurvy, chronic hypothyroidism, congenital or acquired&#xD;
             immunosuppressive condition, chronic renal failure, or chronic hepatic dysfunction&#xD;
             (Child-Pugh class B or C), severe malnutrition, or other concomitant illness which, in&#xD;
             the opinion of the Investigator, has the potential to significantly delay wound&#xD;
             healing)&#xD;
&#xD;
          -  Severe drug and alcohol abuse&#xD;
&#xD;
          -  Pre-existing coagulation disorders as defined by INR outside its normal value, PTT&#xD;
             &gt;ULN and fibrinogen &lt;LLN prior to the current hospital admission and / or at the&#xD;
             Investigator's discretion&#xD;
&#xD;
          -  Patients with known allergies to amphotericin B, gentamicin, penicillin, streptomycin,&#xD;
             or bovine collagen&#xD;
&#xD;
          -  Previous enrolment of the patient into the current phase II study&#xD;
&#xD;
          -  Participation of the patient in another study with conflicting endpoints within 30&#xD;
             days preceding and during the present study&#xD;
&#xD;
          -  Patients expected not to comply with the study protocol (including patients with&#xD;
             severe cognitive dysfunction/impairment and severe psychiatric disorders)&#xD;
&#xD;
          -  Pregnant or breast feeding females&#xD;
&#xD;
          -  Intention to become pregnant during the clinical course of the study (12 months)&#xD;
&#xD;
          -  Enrolment of the Investigator, his/her family members, employees and other dependent&#xD;
             persons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clemens Sc, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University Children's Hospital, Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clemens Schiestl, Prof.</last_name>
    <phone>+41 44 266 73 93</phone>
    <email>clemens.schiestl@kispi.uzh.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chirurgia Plastica e Centro Ustioni Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Petroccione, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Carlo Petroccione, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità di Chirurgia Plastica e Ustioni Ospedale Santobono</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcello Zamparelli, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Marcello Zamparelli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Grandi Ustionati Azienda Ospedale Università Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Azzena, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Bruno Azzena, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Città della Salute</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Stella, Dott.</last_name>
      <phone>+39 11 693 34 25</phone>
    </contact>
    <investigator>
      <last_name>Maurizio Stella, Dott.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Chirurgia Plastica e Centro Ustioni Azienda Ospedaliera Universitaria Integrata Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jasminka Minic, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Jasminka Minic, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Plastic, Reconstructive and Hand Surgery, VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Middelkoop, Prof.</last_name>
      <phone>+31 20 444 4444</phone>
    </contact>
    <investigator>
      <last_name>Esther Middelkoop, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <zip>1940</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Middelkoop, Prof.</last_name>
      <phone>+31 251 265 555</phone>
    </contact>
    <investigator>
      <last_name>Esther Middelkoop, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Böttcher, PD Dr. med.</last_name>
      <phone>+41 44 266 73 93</phone>
    </contact>
    <investigator>
      <last_name>Sophie Böttcher, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rittirsch, PD Dr. med.</last_name>
      <phone>+41 44 255 27 38</phone>
    </contact>
    <investigator>
      <last_name>Daniel Rittirsch, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scar</keyword>
  <keyword>Skin</keyword>
  <keyword>Wound Healing</keyword>
  <keyword>Tissue Engineering</keyword>
  <keyword>Dermis</keyword>
  <keyword>Epidermis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

